Short Summary German-Austrian ART Guidelines 2017 The full version of the German-Austrian ART Guidelines 2017 is accessible under: http://www.daignet.de/site-content/hiv-therapie/leitlinien-1 This file may be used for educational purposes, as long as content and attrition are left unchanged and a reference to the current guideline version is made. Any use for economic purposes requires prior approval of the authors

German-Austrian ART Guidelines 2017 Recommendations for treatment initiation were graded as follows: Grading Explanation To be initiated Treatment is clearly indicated Should be initiated Treatment is indicated, but deferral is justifiable May be initiated Treatment is an option Should not be initiated Treatment is not indicated Recommendations regarding choice of drugs were graded as follows: Grading Explanation Recommended Preferred drug / combination Alternative May be given, may be the best choice for some patients Not recommended Only for special cases, but remains an option Not indicated Is not an option

German-Austrian ART Guidelines 2017 Start of treatment Symptoms CD4+ T cell count ART HIV-associated symptoms and diseases (CDC: C, B), HIVAN1, HAND2, and pregnancy3 Any value To be initiated Asymptomatic patients (CDC: A) < 500/µl > 500/µl Should be initiated Acute retroviral syndrome with prolonged / severe symptoms Asymptomatic/ mild symptoms during seroconversion 1. HIVAN: HIV-associated nephropathy; 2. HAND: HIV-associated neurocognitive disorder, 2. See separate Guidelines for antiretroviral treatment during pregnancy (http://www.daignet.de/site-content/hiv-therapie/leitlinien-1)

German-Austrian ART Guidelines 2017 Combination Partners 1 r Combination Partner 2 Integrase inhibitors Recommended: Dolutegravir Raltegravir Elvitegravir/c*(+TAF/FTC) NNRTI Recommended : Rilpivirine4 (+TAF/FTC) Protease inhibitors Recommended : Darunavir/r# or Darunavir/c* (+TAF/FTC) Alternative: Atazanavir/r# or Atazanavir/c* Nucleoside-/ Nucleotide combinations Recommended: TAF/FTC1 ABC/3TC2 Alternative: TDF/FTC3 TDF + 3TC + not during pregnancy, 2. only with neagative screening for HLA-B*5701; use with care in patients with HIV plasma viremia >100.000 copies/ml or high cardiovascular risk, 3. TDF = tenofovir disproxil fumarate, phosphate, maleate, or succinate, also in in single tablet regimens (TDF/FTC/RPV; TDF/FTC/EVG/c) 4. not if HIV-RNA >100,000 copies/mL (not licensed) */c: Cobicistat, #/r: Ritonavir; TAF = Tenofovir alafenamide, FTC = emtricitabine, ABC = abacavir, 3TC = lamivudine